Skip to main content
OpenTrials
Completed

NCT Number: NCT05925686

Tramadol to Improve Its Detection in Biological Matrices in Anti-doping Controls

Orally single dose administration of Tramadol 75 mg for ultra-rapid metabolizers and 100 mg for extensive and poor metabolizers will be administered with the objective to evaluate urine and blood concentrations in healthy volunteers.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

IMIM (Institut Hospital del Mar d'Investigacions Mèdiques)

Barcelona, 08003, Spain

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 and ≤ 55 years.
  • Weight ≥ 50 kg and ≤ 100 kg.
  • Body mass index (BMI) ≥ 18 and ≤ 30.
  • Negative serum pregnancy test (women only).
  • Signed informed consent prior to any study-mandated procedure.

Exclusion criteria

  • Smoker of more than 5 cigarettes per day in the last 3 months prior to participate in the study.
  • History of psychiatric disorders, alcoholism or drug abuse.
  • Positive urine pregnancy test.
  • No highly effective anticonception measures during the trial.
  • Breastfeeding.
  • Positive blood or urine test for drugs of abuse or alcohol breath test prior to study drug administration.
  • Any clinically relevant disease or condition (cardiovascular, renal, hepatic, endocrine, hematology, neurology o other acute or chronic diseases) that in the judgment of the investigator might interfere with the subject's ability to comply with study procedures or requirements and/or bias the interpretation of the study results and/or jeopardize the subject's safety.
  • Major Surgery last 6 months.
  • Ongoing gastrointestinal diseases or history of gastrointestinal surgery affecting absorption.
  • Subjects with a clinically significant disease within one month prior to study drug administration.
  • Any clinically relevant findings in physical examination, vital signs, 12-lead ECG and safety laboratory parameters.
  • Positive hepatitis or HIV test.
  • Known hypersensitivity to any drug or drug excipients.
  • Use of drugs known to induce or inhibit hepatic drug metabolism within one month prior to study administration or during the study and use of citrus juice during the study.
  • Any prescription or over-the-counter (OTC) product including herbal, homeopathic, vitamins, minerals and nutritional supplements within 2 weeks prior to study drug administration.
  • Intake of more than 5 units per day of beverages containing xanthine (coffee, tea or cola drinks).
  • Donation of blood or plasma within one month prior to study drug administration or transfusion of blood or plasma for medical/surgical reasons or intention to donate blood or plasma within one month after study drug administration.
  • History of inadequate venous access and/or experience of difficulty donating blood.
  • Not able/not willing to accept restrictions regarding diet, physical exercise, and consumption of alcohol and/or xanthine containing items when out of CRU.
  • Subject included in a clinical study within 3 months prior to study drug administration.

Treatment and study plan

Tramadol.

Drug

Orally single dose administration of Tramadol 75 mg for ultra-rapid metabolizers and 100 mg for extensive and poor metabolizers.

Primary outcomes

  1. Urine concentration on Tramadol.

    Time frame: From baseline to 8 hours.

Secondary outcomes

  1. Plasma and dried blood spots (DBS) concentration on Tramadol.

    Time frame: From baseline to 12 hours.

Other outcomes

  1. Adverse effects.

    Time frame: From baseline to 24 hours.

Sponsors and collaborators

Lead sponsor

Parc de Salut Mar

Other

Registry information

Official study title

Tramadol Administered Orally to Healthy Subjects for the Improvement of Its Detection in Biological Matrices in the Context of Anti-Doping Control

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Jun 29, 2023
Registry last updated
Nov 3, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.